ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2021
Genital Powder Use and Risk of Epithelial Ovarian Cancer in the Ovarian Cancer in Women of African Ancestry Consortium.
Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
7 citing papers in PubMed, 11 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
16 authors at 13 institutions in 1 country.
Colette P DavisProgram in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Elisa V BanderaCancer Epidemiology and Health Outcomes, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey.ORCID 0000-0002-8789-2755
Traci N BetheaOffice of Minority Health and Health Disparities Research, Georgetown Lombardi Comprehensive Cancer Center, Georgetown University Medical Campus, Washington, District of Columbia.ORCID 0000-0003-3205-2078
Fabian CamachoDepartment of Public Health Sciences, University of Virginia, Charlottesville, Virginia.
Charlotte E JoslinDepartment of Ophthalmology and Visual Sciences, University of Illinois at Chicago School of Medicine and Division of Epidemiology and Biostatistics, School of Public Health, Chicago, Illinois.
Anna H WuUniversity of Southern California Norris Comprehensive Cancer Center and Department of Preventive Medicine, Keck School of Medicine, Los Angeles, California.
Alicia Beeghly-FadielDepartment of Medicine, Division of Epidemiology, Vanderbilt University Medical Center, Nashville, Tennessee.
Patricia G MoormanDepartment of Family Medicine and Community Health, Duke University Medical Center, Durham, North Carolina.ORCID 0000-0002-2978-6495
Evan R MyersDepartment of Obstetrics and Gynecology, Duke University Medical Center, Durham, North Carolina.ORCID 0000-0002-9053-9864
Heather M Ochs-BalcomDepartment of Epidemiology and Environmental Health, School of Public Health and Health Professions, University at Buffalo, The State University of New York, Buffalo, New York.ORCID 0000-0003-1255-7714
Lauren C PeresDepartment of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.ORCID 0000-0002-6620-8600
Will T RosenowDepartment of Public Health Sciences, University of Virginia, Charlottesville, Virginia.ORCID 0000-0002-0359-8410
Veronica W SetiawanUniversity of Southern California Norris Comprehensive Cancer Center and Department of Preventive Medicine, Keck School of Medicine, Los Angeles, California.
Lynn RosenbergSlone Epidemiology Center at Boston University, Boston, Massachusetts.
Joellen M SchildkrautDepartment of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia.
Holly R HarrisProgram in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington. hharris@fredhutch.org.ORCID 0000-0002-2572-6727
Duke University · USUniversity of Southern California · USUniversity of Virginia · USBoston University · USEmory University · USFred Hutch Cancer Center · USGeorgetown University · USMoffitt Cancer Center · USRutgers, The State University of New Jersey · USUniversity at Buffalo, State University of New York · USUniversity of Illinois Chicago · USUniversity of Washington · USVanderbilt University Medical Center · US
Funding
USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI MYLES G COCKBURN · 1985 to 2026
$181.4M
A Follow-up Study for Causes of Cancer in Black WomenU01CA164974 · NCI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI Kimberly A. Bertrand, Yvette C Cozier · 2017 to 2026
$24.0M
FOLLOW-UP STUDY FOR CAUSES OF ILLNESS IN BLACK WOMENR01CA058420 · NCI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI ROSENBERG, LYNN · 1999 to 2013
$20.7M
USC CANCER EPIDEMIOLOGY &BIOSTATISTICS UNITP01CA017054 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI HENDERSON, BRIAN E · 1985 to 2009
$18.2M
A Follow-up Study for Causes of Cancer in Black WomenUM1CA164974 · NCI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI ROSENBERG, LYNN · 2012 to 2017
$13.7M
Women's Health Initiative Cancer Survivor CohortUM1CA173642 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI ANDERSON, GARNET L., CAAN, BETTE J · 2013 to 2018
$12.1M
Epidemiology of Ovarian Cancer in African-American WomenR01CA142081 · NCI · UNIVERSITY OF VIRGINIA · PI SCHILDKRAUT, JOELLEN M. · 2010 to 2015
$10.6M
WOMEN'S HEALTH INITIATIVE (WHI) REGIONAL CENTER (RC): TASK AREA A AND A275N92021D00002 · NHLBI · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI WACTAWSKI-WENDE, JEAN · 2021 to 2025
$6.9M
The Molecular Epidemiology Of Ovarian CancerR01CA076016 · NCI · DUKE UNIVERSITY · PI SCHILDKRAUT, JOELLEN M. · 1998 to 2010
$6.2M
COLLABORATIVE STUDY OF OVARIAN CANCER IN TWO RISK GROUPSR01CA058598 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI GOODMAN, MARC T · 1993 to 2012
$4.6M
Exploring factors related to racial disparities in ovarian cancer incidence and survival: the OCWAA consortiumR01CA207260 · NCI · UNIVERSITY OF VIRGINIA · PI ROSENBERG, LYNN, SCHILDKRAUT, JOELLEN M. · 2017 to 2020
$2.5M
An assessment of whether aspirin and/or vitamin D improves breast cancer outcomes in Black women and the modifying effect of genetic variantsK01CA212056 · NCI · GEORGETOWN UNIVERSITY · PI BETHEA, TRACI N. · 2017 to 2021
backgroundGenital powder use is more common among African-American women; however, studies of genital powder use and ovarian cancer risk have been conducted predominantly in White populations, and histotype-specific analyses among African-American populations are limited.
methodsWe used data from five studies in the Ovarian Cancer in Women of African Ancestry consortium. Participants included 620 African-American cases, 1,146 African-American controls, 2,800 White cases, and 6,735 White controls who answered questions on genital powder use prior to 2014. The association between genital powder use and ovarian cancer risk by race was estimated using logistic regression.
resultsThe prevalence of ever genital powder use for cases was 35.8% among African-American women and 29.5% among White women. Ever use of genital powder was associated with higher odds of ovarian cancer among African-American women [OR = 1.22; 95% confidence interval (CI) = 0.97-1.53] and White women (OR = 1.36; 95% CI = 1.19-1.57). In African-American women, the positive association with risk was more pronounced among high-grade serous tumors (OR = 1.31; 95% CI = 1.01-1.71) than with all other histotypes (OR = 1.05; 95% CI = 0.75-1.47). In White women, a significant association was observed irrespective of histotype (OR = 1.33; 95% CI = 1.12-1.56 and OR = 1.38; 95% CI = 1.15-1.66, respectively).
conclusionsWhile genital powder use was more prevalent among African-American women, the associations between genital powder use and ovarian cancer risk were similar across race and did not materially vary by histotype. IMPACT: This is one of the largest studies to date to compare the associations between genital powder use and ovarian cancer risk, overall and by histotype, between African-American and White women.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Genital Powder Use and Risk of Epithelial Ovarian Cancer in the Ovarian Cancer in Women of African Ancestry Consortium. · full record | OpenQuestion